[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO3037424T3 - - Google Patents

Info

Publication number
NO3037424T3
NO3037424T3 NO14837210A NO14837210A NO3037424T3 NO 3037424 T3 NO3037424 T3 NO 3037424T3 NO 14837210 A NO14837210 A NO 14837210A NO 14837210 A NO14837210 A NO 14837210A NO 3037424 T3 NO3037424 T3 NO 3037424T3
Authority
NO
Norway
Application number
NO14837210A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3037424T3 publication Critical patent/NO3037424T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NO14837210A 2013-08-22 2014-08-22 NO3037424T3 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013172746 2013-08-22
PCT/JP2014/071951 WO2015025936A1 (ja) 2013-08-22 2014-08-22 新規キノリン置換化合物

Publications (1)

Publication Number Publication Date
NO3037424T3 true NO3037424T3 (no) 2018-04-07

Family

ID=52483707

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14837210A NO3037424T3 (no) 2013-08-22 2014-08-22

Country Status (22)

Country Link
US (2) US9650386B2 (no)
EP (1) EP3037424B1 (no)
JP (1) JP6161705B2 (no)
KR (1) KR101906688B1 (no)
CN (1) CN105683195B (no)
AU (1) AU2014309788B2 (no)
BR (1) BR112016003247B1 (no)
CA (1) CA2922077C (no)
DK (1) DK3037424T3 (no)
ES (1) ES2656712T3 (no)
HK (1) HK1222393A1 (no)
HU (1) HUE034807T2 (no)
MX (1) MX370808B (no)
MY (1) MY182891A (no)
NO (1) NO3037424T3 (no)
PH (1) PH12016500225A1 (no)
PL (1) PL3037424T3 (no)
PT (1) PT3037424T (no)
RU (1) RU2689158C2 (no)
SG (1) SG11201600759XA (no)
TW (1) TWI603971B (no)
WO (1) WO2015025936A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105683195B (zh) * 2013-08-22 2017-11-10 大鹏药品工业株式会社 喹啉取代的化合物
JOP20190073A1 (ar) * 2016-10-31 2019-04-07 Taiho Pharmaceutical Co Ltd مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20
BR112019010020A2 (pt) * 2016-11-17 2019-08-20 Univ Texas compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
FR3068971B1 (fr) * 2017-07-12 2019-08-30 Protneteomix Acides 5-{4-allyl-5-[2-(4-alcoxyphenyl)quinolein-4-yl]-4h-1,2,4-triazole-3-ylsulphanylmethyl}furan-2-carboxyliques dans le traitement du cancer
CN117159551A (zh) 2017-09-01 2023-12-05 大鹏药品工业株式会社 外显子18和/或外显子21突变型egfr的选择性抑制剂
TWI837266B (zh) * 2018-12-28 2024-04-01 日商大鵬藥品工業股份有限公司 L718及/或l792突變型治療抗性egfr抑制劑
JP7109013B2 (ja) 2019-03-19 2022-07-29 ボロノイ インコーポレイテッド ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物
CN112574208B (zh) * 2019-09-29 2022-09-13 深圳市塔吉瑞生物医药有限公司 取代的稠合三环衍生物及其组合物及用途
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
CN113861195B (zh) * 2020-06-30 2022-11-18 上海和誉生物医药科技有限公司 一种多稠环egfr抑制剂及其制备方法和应用
CN116096372B (zh) * 2020-07-09 2024-09-03 上海和誉生物医药科技有限公司 一种egfr抑制剂、其制备方法和在药学上的应用
US20230372346A1 (en) * 2020-09-08 2023-11-23 Cullinan Pearl Corp. Treatment regimens for exon-20 insertion mutant egfr cancers
WO2022121967A1 (zh) * 2020-12-09 2022-06-16 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
EP4355330A1 (en) 2021-06-15 2024-04-24 Genentech, Inc. Egfr inhibitor and perk activator in combination therapy and their use for treating cancer
CN115707704B (zh) * 2021-08-20 2024-09-13 广东医诺维申生物技术有限公司 氘代稠合三环类化合物及其组合物和用途
WO2024121805A1 (en) * 2022-12-08 2024-06-13 Assia Chemical Industries Ltd. Solid state forms of zipalertinib and process for preparation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW440562B (en) 1994-05-20 2001-06-16 Taiho Pharmaceutical Co Ltd Condensed-indan derivative and pharmaceutically acceptable salts thereof
MX2007011435A (es) * 2005-03-17 2007-12-05 Novartis Ag N-[3-(1-amino-5,6,7,8-tetrahidro-2,4,4b-triazafluoren-9-il)-fenil ]-benzamidas como inhibidores de cinasa de tirosina/treonina, en particular de cinasa b-raf.
PT2452940E (pt) 2009-07-10 2015-02-27 Taiho Pharmaceutical Co Ltd Composto azabiciclo e seu sal
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
JP5792201B2 (ja) 2011-01-07 2015-10-07 大鵬薬品工業株式会社 新規二環式化合物又はその塩
EP2762476A4 (en) 2011-09-30 2015-03-25 Taiho Pharmaceutical Co Ltd 1,2,4-triazine-6-carboxamide derivative
TWI594986B (zh) * 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
WO2013118817A1 (ja) * 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩
PL2722332T3 (pl) * 2012-02-23 2016-10-31 Związek chinolilopirolopirymidylowy ze sprzężonym pierścieniem lub jego sól
MX2015010934A (es) 2013-02-22 2015-10-29 Taiho Pharmaceutical Co Ltd Metodo para producir un compuesto triciclico, y un compuesto triciclico capaz de producirse por dicho metodo de produccion.
CN105683195B (zh) * 2013-08-22 2017-11-10 大鹏药品工业株式会社 喹啉取代的化合物

Also Published As

Publication number Publication date
US20170101414A1 (en) 2017-04-13
EP3037424A1 (en) 2016-06-29
JP6161705B2 (ja) 2017-07-12
EP3037424B1 (en) 2017-11-08
CN105683195A (zh) 2016-06-15
US9758526B2 (en) 2017-09-12
BR112016003247B1 (pt) 2022-05-10
RU2019114688A (ru) 2020-07-29
DK3037424T3 (en) 2017-12-11
PH12016500225B1 (en) 2016-05-02
BR112016003247A2 (no) 2017-08-01
US9650386B2 (en) 2017-05-16
RU2689158C2 (ru) 2019-05-24
PT3037424T (pt) 2017-12-18
AU2014309788A1 (en) 2016-03-10
TWI603971B (zh) 2017-11-01
MY182891A (en) 2021-02-05
PH12016500225A1 (en) 2016-05-02
RU2016110096A (ru) 2017-09-27
MX370808B (es) 2020-01-07
ES2656712T3 (es) 2018-02-28
EP3037424A4 (en) 2017-01-25
AU2014309788B2 (en) 2017-02-16
MX2016002125A (es) 2016-06-28
CN105683195B (zh) 2017-11-10
SG11201600759XA (en) 2016-03-30
KR101906688B1 (ko) 2018-10-10
CA2922077A1 (en) 2015-02-26
PL3037424T3 (pl) 2018-03-30
HK1222393A1 (zh) 2017-06-30
HUE034807T2 (en) 2018-02-28
JPWO2015025936A1 (ja) 2017-03-02
RU2016110096A3 (no) 2018-06-18
US20160194332A1 (en) 2016-07-07
TW201542547A (zh) 2015-11-16
WO2015025936A1 (ja) 2015-02-26
CA2922077C (en) 2018-06-26
KR20160043114A (ko) 2016-04-20

Similar Documents

Publication Publication Date Title
AP2016009275A0 (no)
BR112016014083A2 (no)
BR112015007533A2 (no)
BR112016010832A2 (no)
BR102016010778A2 (no)
BR112016011851A2 (no)
BR112014017733A2 (no)
BR112014017739A2 (no)
BR112016008452A2 (no)
BR112014017669A2 (no)
BR112016005150A2 (no)
BR112016011085A2 (no)
BR112016013169A2 (no)
RU2016110096A3 (no)
BR112015030872A2 (no)
BR112014017722A2 (no)
BR112015015948A2 (no)
BR112015023202A2 (no)
BR112014017653A2 (no)
BR112015015312A2 (no)
BR112016008778A2 (no)
BR112014024039A2 (no)
BR112016009822A2 (no)
BR112016013075A2 (no)
BR112016003783A2 (no)